Shares of Athenex Inc (NASDAQ:ATNX) have been assigned an average rating of “Buy” from the six research firms that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $24.00.

A number of research firms have weighed in on ATNX. Zacks Investment Research raised shares of Athenex from a “sell” rating to a “hold” rating in a research report on Tuesday, October 16th. BidaskClub upgraded shares of Athenex from a “sell” rating to a “hold” rating in a report on Wednesday, November 28th. LADENBURG THALM/SH SH started coverage on shares of Athenex in a report on Thursday, October 25th. They set a “buy” rating and a $27.00 price objective on the stock. Finally, JPMorgan Chase & Co. upgraded shares of Athenex from a “neutral” rating to an “overweight” rating and dropped their price objective for the stock from $24.00 to $15.00 in a report on Thursday, November 15th.

ATNX stock opened at $12.05 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 4.46 and a quick ratio of 3.86. Athenex has a 1 year low of $9.83 and a 1 year high of $20.90. The firm has a market capitalization of $806.07 million, a P/E ratio of -5.19 and a beta of 0.13.

Athenex (NASDAQ:ATNX) last released its earnings results on Wednesday, November 14th. The company reported ($0.33) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.12. The firm had revenue of $18.43 million during the quarter. Athenex had a negative net margin of 143.42% and a negative return on equity of 71.94%. Equities analysts forecast that Athenex will post -1.98 earnings per share for the current year.

In other Athenex news, insider Jeffrey Yordon bought 9,500 shares of the stock in a transaction that occurred on Wednesday, November 14th. The shares were acquired at an average price of $10.49 per share, with a total value of $99,655.00. Following the completion of the purchase, the insider now directly owns 198,209 shares in the company, valued at approximately $2,079,212.41. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Johnson Yiu Nam Lau bought 40,000 shares of the stock in a transaction that occurred on Wednesday, November 14th. The stock was acquired at an average cost of $10.47 per share, for a total transaction of $418,800.00. Following the purchase, the chief executive officer now owns 2,887,422 shares of the company’s stock, valued at $30,231,308.34. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 71,500 shares of company stock worth $762,815. Insiders own 29.50% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc increased its stake in Athenex by 363.2% in the second quarter. Legal & General Group Plc now owns 6,930 shares of the company’s stock valued at $129,000 after acquiring an additional 5,434 shares during the period. Tower Research Capital LLC TRC bought a new stake in Athenex in the third quarter valued at about $146,000. Prudential Financial Inc. bought a new stake in Athenex in the fourth quarter valued at about $147,000. KCS Wealth Advisory increased its stake in Athenex by 8.9% in the fourth quarter. KCS Wealth Advisory now owns 12,182 shares of the company’s stock valued at $155,000 after acquiring an additional 1,000 shares during the period. Finally, Man Group plc bought a new stake in Athenex in the third quarter valued at about $201,000. 25.03% of the stock is currently owned by institutional investors and hedge funds.

About Athenex

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.

Recommended Story: NASDAQ

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.